NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Quinolone-Resistant E. coli Bacteremia from One University Hospital in Korea.

CHUNG HJ, YU CW, PARK KH, SOHN JW, KIM WJ, KIM MJ, PARK SC; Interscience Conference on Antimicrobial Agents and Chemotherapy.

Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1999 Sep 26-29; 39: 179 (abstract no. 2260).

Dept. of Internal Med., Korea Univ. Med. Coll., Seoul, REPUBLIC OF KOREA.

The frequent use of norfloxacin has been associated with the emergence of quinolone-resistant E. coli in the community as well as in the hospital. Recently, we have observed increasing resistance to ciprofloxacin among E. coli strains isolated from blood cultures in our hospitals. Thus we decided to define the risk factors, clinical features and prognosis of ciprofloxacin-resistant E. coli bacteremia. All patients with E. coli isolated from blood during 5-year period, were classified according to case (ciprofloxacin-resistant) and controls (ciprofloxaicn-resistant). During the study period (Sept 1993 - Aug. 1998), 11.5% (40 of 349 episodes) of E. coli bacteremia were due to ciprofloxacin resistant E. coli strains. We observed a sharp increase in ofloxacin and ciprofloxacin consumption in the hospital from 177.1 to 241.7 AUD and a positive correlation between AUD of quinolone and the incidence of ciprofloxacin-resistant E. coli bacteremia (p=0.037, R=0.900). The 40 case patients were compared with 80 control patients with ciprofloxacin susceptible E. coli bacteremia. Case patients were more likely than control patients to have a underlying disease (83%, p=0.000); malignancy (55%, p=0.001), hematologic disease (23%, p=0.000), liver cirrhosis(30%, p=0.025). Prior use of urinary catheter (25%, p=0.010), non-quinolone antibiotics (48%, p=0.000), quinolone (78%, p=0.000), and steroid (30%, p=0.006) were significantly associated with ciprofloxacin-resistant E. coli bacteremia. By multivariate analysis, prior quinolone use was only independent risk factor for the development of ciprofloxacin-resistant E. coli bacteremia. The overall mortality rates were 30% for ciprofloxacin-resistant E. coli bacteremia and 16% for ciprofloxacin susceptible E. coli bacteremia, the difference is significant.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Bacteremia
  • Ciprofloxacin
  • Hospitals, University
  • Humans
  • Incidence
  • Korea
  • Norfloxacin
  • Ofloxacin
  • Risk Factors
Other ID:
  • GWAIDS0007593
UI: 102245089

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov